Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Mark Ragosa Sells 8,879 Shares

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 8,879 shares of Kiniksa Pharmaceuticals stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $23.10, for a total value of $205,104.90. Following the completion of the sale, the chief financial officer now directly owns 23,382 shares in the company, valued at $540,124.20. This trade represents a 27.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Mark Ragosa also recently made the following trade(s):

• On Monday, March 17th, Mark Ragosa sold 11,464 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $23.10, for a total value of $264,818.40.
• On Wednesday, March 12th, Mark Ragosa sold 36,372 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $22.25, for a total value of $809,277.00.

Kiniksa Pharmaceuticals Stock Performance

KNSA stock traded down $0.45 during mid-day trading on Friday, reaching $23.36. 435,145 shares of the stock traded hands, compared to its average volume of 406,548. The business has a 50-day moving average price of $20.30 and a two-hundred day moving average price of $22.04. The stock has a market capitalization of $1.70 billion, a PE ratio of -166.85 and a beta of 0.48. Kiniksa Pharmaceuticals, Ltd. has a one year low of $16.56 and a one year high of $28.15.

Remove Ads

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $122.50 million during the quarter, compared to analysts' expectations of $123.42 million. During the same period last year, the company earned $0.35 earnings per share. The business's revenue for the quarter was up 46.9% compared to the same quarter last year. On average, equities analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Citigroup began coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 price target on the stock. Wedbush restated an "outperform" rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $37.17.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Quarry LP bought a new position in Kiniksa Pharmaceuticals in the 3rd quarter valued at $50,000. Lazard Asset Management LLC purchased a new position in Kiniksa Pharmaceuticals during the 4th quarter valued at about $61,000. KLP Kapitalforvaltning AS bought a new position in shares of Kiniksa Pharmaceuticals in the 4th quarter worth $158,000. Bellevue Group AG purchased a new stake in Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $160,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of Kiniksa Pharmaceuticals by 117.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock worth $168,000 after acquiring an additional 4,575 shares during the last quarter. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.